Dan Hui Lu from 2160 Madison St, New York, NY 10037, age 44

Resumes

Dan Lu Richardson, TX

view source

Work:

DFW Excellerator

Mar 2014 to 2000
Organization member Friendship Association of Chinese Students and Scholars at UT-Dallas

Aug 2013 to 2000
Member in Career Planning Department Friendship Association of Chinese Students and Scholars at UT-Dallas
Dallas, TX
Feb 2014 to Apr 2014
Volunteer Income Tax Assistance Diyuan Powder Metallurgy Furnace Co., Ltd
Mumbai, Maharashtra
May 2013 to Jul 2013
JOB & INTERNSHIP CITI Bank Talent Young Program
Changsha, CN
Apr 2013 to Apr 2013
Group leader and organizer Hunan Jianye Certified Public Accountants Company Limited
Changsha, CN
May 2012 to Apr 2013
Assistant in Auditing Department, Group China Construction Bank Corporation
Zhuzhou, CN
Dec 2011 to Mar 2012
Assistant and Consultant in Sales Department (intern)

Education:

University of Texas at Dallas, Naveen Jindal School of Management
Dallas, TX
Aug 2013
Master of Science in Accounting Central South University of Forestry and Technology, Commercial College
Sep 2008 to Jun 2012
Bachelor of Management in Accounting

Name / Title

Company / Classification

Phones & Addresses

Dan Lu
Director

NO 1 CHINESE RESTAURANT INC. OF LT

6601 Old Winter Gdn Rd STE 106, Orlando, FL 32835
6638 Sawyer Shr Ln, Windermere, FL 34786

Dan Lu
Family Practitioner

Doctors Immedicare
Doctor · Surgeons · Family Doctor

199 Hempstead Tpke, Hempstead, NY 11552
5165654110

Dan Lu
Internal Medicine

Family Medical Health LLC
Medical Doctor's Office

24818 Un Tpke, Jamaica, NY 11426
7183477621

Us Patents

Anti-Flt3 Antibodies
view source
US Patent:

8071099, Dec 6, 2011
Filed:

Sep 27, 2010
Appl. No.:

12/890793
Inventors:

Yiwen Li - Jersey City NJ, US
Dan Lu - Montvale NJ, US
David Surguladze - Chatham NJ, US
James Robert Tonra - Skillman NJ, US
Assignee:

ImClone, LLC - New York NY
International Classification:

A61K 39/395
A61K 39/00
C07K 16/24
C12N 5/10
US Classification:

4241451, 4241301, 4241391, 4241411, 435 691, 435325, 435326, 435331, 5303879, 5303881, 53038823
Abstract:

The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

Anti-Flt3 Antibodies
view source
US Patent:

20090297529, Dec 3, 2009
Filed:

May 28, 2009
Appl. No.:

12/473295
Inventors:

Yiwen Li - Jersey City NJ, US
Dan Lu - Montvale NJ, US
James Robert Tonra - Skillman NJ, US
David Surguladze - Chatham NJ, US
International Classification:

A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/63
C12N 5/10
C12P 21/06
US Classification:

4241391, 5303879, 536 2353, 4353201, 435325, 435 696
Abstract:

The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

Anti-Flt3 Antibodies
view source
US Patent:

20110091470, Apr 21, 2011
Filed:

May 28, 2009
Appl. No.:

12/994956
Inventors:

Yiwen Li - Jersey City NJ, US
Dan Lu - Montvale NJ, US
David Surguladze - Chatham NJ, US
James Robert Tonra - Skillman NJ, US
Assignee:

IMCLONE LLC - P.O. Box 6288 IN
International Classification:

A61K 39/395
C07K 16/18
A61P 35/00
A61P 35/02
US Classification:

4241391, 5303879, 5303917, 5303913
Abstract:

The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

Immunomodulatory Agents
view source
US Patent:

20210022773, Jan 28, 2021
Filed:

Mar 9, 2020
Appl. No.:

16/812867
Inventors:

- NEW YORK NY, US
Zhenping Zhu - Woodcliff Lake NJ, US
Yan Wu - Doylestown PA, US
Stella A. Martomo - Edgewater NJ, US
Zhaojing Zhong - Bronx NY, US
Dan Lu - Montvale NJ, US
International Classification:

A61B 17/70
Abstract:

The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL 15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Human Anti-Vegfr-2/Kdr Antibodies
view source
US Patent:

20180346579, Dec 6, 2018
Filed:

Jun 14, 2018
Appl. No.:

16/008744
Inventors:

- NEW YORK NY, US
Dan Lu - Montvale NJ, US
Zhanna Polonskaya - Mountainside NJ, US
International Classification:

C07K 16/28
A61K 45/06
A61K 39/395
Abstract:

The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Immunomodulatory Agents
view source
US Patent:

20160340429, Nov 24, 2016
Filed:

Jan 15, 2015
Appl. No.:

15/111102
Inventors:

- New York NY, US
Zhenping ZHU - Woodcliff Lake NJ, US
Yan WU - Doylestown PA, US
Stella MARTOMO - Edgewater NJ, US
Zhaojing ZHONG - Bronx NY, US
Dan LU - Montvale NJ, US
International Classification:

C07K 16/28
A61K 47/48
C07K 14/54
Abstract:

The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Human Anti-Vegfr-2/Kdr Antibodies
view source
US Patent:

20150284464, Oct 8, 2015
Filed:

Oct 7, 2013
Appl. No.:

14/431954
Inventors:

- New York NY, US
Dan Lu - Montvale NJ, US
International Classification:

C07K 16/28
A61K 45/06
A61K 39/395
Abstract:

The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Medicine Doctors

Dr. Dan Lu, West Hempstead NY - MD (Doctor of Medicine)

view source

Specialties:

Geriatric Medicine

Address:

Doctors Premiere Care
199 Hempstead Tpke, West Hempstead, NY 11552
5165654110 (Phone)

Languages:

English
Chinese

Hospitals:

Doctors Premiere Care
199 Hempstead Tpke, West Hempstead, NY 11552

Franklin Hospital
900 Franklin Avenue, Valley Stream, NY 11580

Long Island Jewish Medical Center
270 05 76Th Avenue, New Hyde Park, NY 11040

Mercy Medical Center
1000 North Village Avenue, Rockville Centre, NY 11570

Education:

Medical School
Suzhou Medical College
Graduated: 1984
Medical School
Bronx Vamc
Graduated: 1996
Medical School
Bronx Vamc
Graduated: 1997
Medical School
Winthrop Hospital
Graduated: 1998
Medical School
Winthrop Hospital
Graduated: 1999

Dan Lu

view source

Specialties:

Internal Medicine

Work:

Doctors Premiere Care
199 Hempstead Tpke, West Hempstead, NY 11552
5165654110 (phone), 5165653313 (fax)

Education:

Medical School
Suzhou Med Coll, Suzhou City, Jiangsu, China
Graduated: 1984

Procedures:

Continuous EKG
Electrocardiogram (EKG or ECG)
Hearing Evaluation
Nutrition Therapy
Pulmonary Function Tests
Vaccine Administration

Conditions:

Acute Conjunctivitis
Acute Pharyngitis
Acute Sinusitis
Acute Upper Respiratory Tract Infections
Anxiety Phobic Disorders

Languages:

Chinese
English
Spanish

Description:

Dr. Lu graduated from the Suzhou Med Coll, Suzhou City, Jiangsu, China in 1984. She works in West Hempstead, NY and specializes in Internal Medicine. Dr. Lu is affiliated with Long Island Jewish Valley Stream.